Core Viewpoint - Royal Philips and Medtronic Neurovascular have formed a strategic advocacy partnership to improve stroke care globally, emphasizing the importance of timely diagnosis and treatment to save lives and reduce long-term disability [1][4]. Group 1: Partnership and Advocacy - Philips and Medtronic Neurovascular have joined the World Stroke Organization Advocacy Coalition to collaborate with various stakeholders in addressing the global burden of stroke [2][6]. - The partnership aims to raise awareness about stroke symptoms and the necessity of immediate care, improve access to treatment, and leverage technology for integrated stroke care systems [3][5]. Group 2: Stroke Impact and Economic Burden - Stroke affects an estimated 12 million people globally each year, with direct and indirect costs estimated at around USD 900 billion annually, expected to nearly double in the next 25 years [3]. - The collaboration seeks to establish a global network of stroke care centers to provide comprehensive care from early diagnosis to rehabilitation [3]. Group 3: Upcoming Initiatives and Events - The collaboration will be showcased at the World Stroke Congress in Abu Dhabi, where both companies will host a Stroke Advocacy roundtable session [4]. - The partnership builds on previous joint efforts at significant events like the United Nations General Assembly, advocating for increased investments in stroke care infrastructure [4].

Medtronic (MDT) closed at $91.12 in the latest trading session, marking a +0.1% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.05% for the day. Elsewhere, the Dow lost 0.02%, while the tech-heavy Nasdaq added 0.18%. Prior to today's trading, shares of the medical device company had gained 1.3% over the past month. This has outpaced the Medical sector's loss of 4.16% and lagged the S&P 500's gain of 2.76% in that time. Investors will be eagerly watching for the performa ...

Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or Abbott (ABT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revis ...

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios. Navigating this market can be a tricky endeavor. For one thing, there is plenty of interest rate uncertainty given the Fed's delicate balancing act of contr ...

Following a slump, shares of Medtronic (MDT) seem to have started to recuperate, possibly banking on a gradually improving investment and research scenario, thanks to the recent monetary policy easing. Closing Wednesday's trading session at $88.14, shares of this MedTech behemoth are currently trading near the 52-week high of $91.49. Fed's latest aggressive 50-bps rate cut, along with the high likelihood of another half a percentage point cut in the rest of 2024, as part of the central bank's gradual unwind ...

For Immediate ReleasesChicago, IL – October 9, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include:JPMorgan Chase & Co. (JPM) , Medtronic plc (MDT) and Shopify Inc. (SHOP) and Perma-Pipe International Holdings, Inc. (PPIH) .Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for JPMorgan Chase, Med ...

Core Points - Medtronic has issued a voluntary field action regarding its MiniMed™ 600 and 700 series insulin pumps due to reports of shortened battery life and potential health risks associated with battery alerts and insulin delivery interruptions [1][2][3] - The FDA has classified this action as a class I recall, indicating a significant risk to patient safety [1] - Medtronic emphasizes the importance of patient safety and has established a 24/7 support system for users experiencing battery issues [3] Summary by Sections Product Issue - Customers are advised to monitor built-in alerts for battery status and contact Medtronic for pump replacement if they notice changes in battery life [1] - A comprehensive analysis revealed that physical impacts to the pump can lead to reduced battery life and premature battery alerts [1][2] - Medtronic has received 170 reports of hyperglycemia and 11 reports of diabetic ketoacidosis potentially related to this issue from January 2023 to September 2024 [1] Customer Guidance - Users should be prepared to replace the battery immediately upon receiving a "Low Battery Pump" alarm, as the pump may stop insulin delivery sooner than expected [2] - It is recommended that users carry extra batteries and have backup therapy available [2] Company Commitment - Medtronic prioritizes patient safety and continuity of therapy, actively notifying impacted users since July 2024 [3] - The company is committed to replacing pumps when necessary and providing ongoing support to users [3] Company Overview - Medtronic is a global leader in healthcare technology, aiming to transform diabetes care and improve patient outcomes [4][5] - The company employs over 95,000 people across more than 150 countries, addressing various health conditions with innovative technologies [5][6]

Medtronic plc’s (MDT) growth is backed by remarkable progress within the Neurosurgery Portfolio. The company’s continuous efforts to capture several growth markets look impressive. Meanwhile, headwinds from adverse foreign exchange effects pose a challenge to Medtronic’s operations. Mounting costs and expenses due to geopolitical conditions also add to the worry.In the past year, this Zacks Rank #3 (Hold) stock has risen 15.6% compared with the industry’s 24.2% growth. The S&P 500 composite has witnessed a ...

Medtronic plc (MDT) has shared late-breaking clinical trial results for its PulseSelect Pulsed Field Ablation (“PFA”) system, demonstrating a high rate of durable lesion formation in treating atrial fibrillation (Afib). The findings were presented at the Asia Pacific Heart Rhythm Society meeting held in Sydney, Australia.The widespread adoption of PulseSelect also continues, with more than 10,000 cases having been performed worldwide.Predicting MDT Stock Movement Following the NewsAfter the announcement, Me ...

APHRS: New data confirm robust long-term durability and highly efficient procedure performed without fluoroscopySuccessful launch in Japan follows recent reimbursement approval  Approvals across APAC including China and Australia broaden reach for patientsGALWAY, Ireland and SYDNEY, Sept. 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high rate of durable lesion formation for the PulseSe ...